TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20980998
Drug: Twice-daily kisspeptin-54
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily kisspeptin-54 (KP-54) injections
Study: 18591698
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil (FA) 1 mg.kg(‐1) iv, 30 min before and six hours after skin incision
Study: 17380846
Drug: Dihydropyridines (DHP)
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridines (DHP) treatment
Study: 8646827
Drug: Enalaprilat infusion
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalaprilat infusion in small dorsal hand veins at skin temperatures < 29.0 degrees C
Study: 8646827
Drug: Enalaprilat infusion
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalaprilat infusion in small dorsal hand veins at skin temperatures > 31 degrees C with norepinephrine preconstriction
Study: 8646827
Drug: Insulin-mediated vasodilation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-mediated vasodilation
Study: 1633323
Drug: ASA 300
Normalized name: ASA 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 300 mg daily
Study: 1633323
Drug: ASA 500
Normalized name: ASA 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 500 mg twice daily
Study: 6500225
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg four times a day
Study: 31704789
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with continuous infusion of 0.2% levobupivacaine (8 mL/hour) after a 20 mL bolus.
Study: 31704789
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block (TPVB) with continuous infusion of 0.2% levobupivacaine (8 mL/hour) after a 20 mL bolus.
Study: 29190357
Drug: Telephone-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive-behavioral therapy (CBT), 12 sessions of 50 minutes each over 6 months
Study: 25104527
Drug: Edoxaban high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban high dose
Study: 25104527
Drug: Edoxaban low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban low dose
Study: 7751734
Drug: Lomefloxacin (LFLX)
DrugBank: Lomefloxacin (DB00978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomefloxacin (LFLX) 100 mg or 300 mg, administered as a single dose.
Study: 2303583
Drug: Ibuprofen/codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/codeine
Study: 2303583
Drug: Aspirin/codeine
Normalized name: ASPIRIN/CODEINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/codeine
Study: 2303583
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatment groups (including ibuprofen/codeine and aspirin/codeine)
Study: 30553570
Drug: MF59-adjuvanted A(H5N1)
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted A(H5N1) vaccine
Study: 30553570
Drug: Unadjuvanted A(H5N1)
Normalized name: influenza A virus (H5N1) antigen Prefilled Syringe [Audenz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted A(H5N1) vaccine
Study: 30553570
Drug: A(H5N1) vaccine
Normalized name: hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A(H5N1) vaccine antigen
Study: 25133644
Drug: 36 hours
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36 hours after hCG injection
Study: 25133644
Drug: 42 hours
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 42 hours after hCG injection
Study: 25133644
Drug: 48 hours
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 hours after hCG injection
Study: 21546726
Drug: Primary closure
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary closure with omental patch
Study: 19366848
Drug: Nestorone (NES)
Normalized name: Ne
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone (NES) gel 2 mg
Study: 19366848
Drug: Nestorone (NES)
Normalized name: Ne
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone (NES) gel 4 mg
Study: 19366848
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) gel 10 g
Study: 19366848
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 10 g plus NES gel 2 mg
Study: 19366848
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 10 g plus NES gel 4 mg
Study: 19366848
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 10 g plus NES gel 6 mg
Study: 19366848
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 10 g plus NES gel 8 mg
Study: 18190254
Drug: Recombinant EBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3‐O‐desacyl‐4'‐monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen
Study: 11480325
Drug: Low-sodium hypotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium hypotonic oral rehydration solution (LSORS)
Study: 11480325
Drug: Standard WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO oral rehydration solution (STORS)
Study: 7974683
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment alone (ABZ CE group)
Study: 2786292
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin calcium 25 mg (formulation 1)
Study: 2786292
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin calcium 25 mg (formulation 2)
Study: 5795804
Drug: Pentazocine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (10 mg, 20 mg, 40 mg)
Study: 5795804
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg, 10 mg)
Study: 27080998
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (ES) of auricular acupressure, performed twice a week for 4 weeks at each acupoint for 30 seconds.
Study: 19372329
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 4 ng/mL (Group R4)
Study: 19372329
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 2 ng/mL (Group R2)
Study: 19372329
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 3 ng/mL (Group R3)
Study: 19372329
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 1 ng/mL (Group R1)
Study: 11672921
Drug: 7-valent conjugate
Normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent conjugate vaccine (conjugate-conjugate)
Study: 11672921
Drug: 7-valent conjugate
Normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent conjugate vaccine followed by 23-valent polysaccharide vaccine (conjugate-polysaccharide)
Study: 9039508
Drug: Methylprednisolone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (4 mg/kg/day)
Study: 3111615
Drug: Methenamine hippurate
Normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine hippurate (1 g twice daily)
Study: 22302136
Drug: Once-weekly etanercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly etanercept (OW) 25 mg
Study: 22302136
Drug: Twice-weekly etanercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly etanercept (TW) 25 mg
Study: 15881624
Drug: Quetiapine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine treatment (up to 600 mg/day)
Study: 15881624
Drug: Quetiapine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine treatment
Study: 12021647
Drug: Superior ophthalmic
Normalized name: Sus scrofa superior gastric plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superior ophthalmic vein dilation
Study: 10705056
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid 500 mg q8h orally for 7 days
Study: 10705056
Drug: No anti-staphylococcal
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-staphylococcal treatment (Control)
Study: 17225720
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid treatment
Study: 8443851
Drug: Rocuronium cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium cumulative dose-response
Study: 30321440
Drug: Psychosensory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosensory therapy (Havening)
Study: 30321440
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no psychosensory therapy)
Study: 24436454
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine at 4.5 months
Study: 22974788
Drug: Enalapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ACE inhibitor) for 6 weeks
Study: 20303115
Drug: Amitriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10 to 75 mg once daily over 6 weeks)
Study: 20303115
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg or greater)
Study: 18998329
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids therapy (beclomethasone dipropionate or fluticasone propionate)
Study: 15738024
Drug: Antibiotics effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics effective against Chlamydia (excluded from analysis)
Study: 15738024
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (control group of women not receiving antibiotics)
Study: 10642678
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin (200 microg/kg body weight)
Study: 10642678
Drug: Topical permethrin
Normalized name: permethrin Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical permethrin cream (5%)
Study: 8839911
Drug: EO9 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: EO9 12 mg/m2 weekly (arm A)
Study: 8839911
Drug: EO9 22
Approvals — FDA: no, EMA: no, PMDA: no
Description: EO9 22 mg/m2 every three weeks (arm B)
Study: 26778544
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (PJ) 200 mL/d for 21 days
Study: 26778544
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice diluted 1:1 with water (PJD) 200 mL/d for 21 days
Study: 24266855
Drug: Reduced-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose cyclosporine (rCsA) with sirolimus and corticosteroids
Study: 24266855
Drug: Standard-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclosporine (sCsA) with sirolimus and corticosteroids
Study: 22908696
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid tablets
Study: 9096964
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and glyburide (1.25-2.5 mg/day)
Study: 3516511
Drug: muzolimine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine, 20 mg/day
Study: 3516511
Drug: hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide, 50 mg/day and amiloride, 5 mg/day
Study: 30304013
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release (ER) onapristone 50 mg BID
Study: 30304013
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release 100 mg QD
Study: 24387919
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A - scan delay of 65 s after starting contrast injection over 30 s
Study: 24387919
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B - scan delay of 105 s after starting contrast injection over 70 s
Study: 24387919
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C - scan delay of 145 s after starting contrast injection over 110 s
Study: 16567931
Drug: Warfarin (adjusted-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted-dose, INR 1.4-2.8)
Study: 12587093
Drug: NRTI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI therapy
Study: 12587093
Drug: Control (treatment-naive)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (treatment-naive)
Study: 10879578
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment (4 sessions of relaxation and stimulus control)
Study: 8792889
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of bupivacaine 2.5 mg/ml with 3 mg of morphine (Group I)
Study: 8792889
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of bupivacaine 2.5 mg/ml (Group II)
Study: 8792889
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml isotonic saline with 3 mg morphine (Group III)
Study: 8792889
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of isotonic saline (placebo, Group IV)
Study: 1627201
Drug: sertaconazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertaconazole 1% cream
Study: 1627201
Drug: sertaconazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertaconazole 2% cream
Study: 18823217
Drug: Etravirine 100
Normalized name: etravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 100 mg after a fasted state
Study: 18823217
Drug: Etravirine 100
Normalized name: etravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 100 mg after a light breakfast (croissant)
Study: 18823217
Drug: Etravirine 100
Normalized name: etravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 100 mg after an enhanced-fiber breakfast
Study: 18823217
Drug: Etravirine 100
Normalized name: etravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 100 mg after a high-fat breakfast
Study: 14724827
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg daily 1 week before chemotherapy (group 1)
Study: 14724827
Drug: Deferred lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Deferred lamivudine treatment until serological evidence of hepatitis B virus reactivation (group 2)
Study: 14724827
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment (group 1)
Study: 16685181
Drug: Early Intensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Intensive Behavioral Treatment (EIBT)
Study: 11737006
Drug: Intramuscular needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular needle insertions into six designated trigger points
Study: 11737006
Drug: Subcutaneous insertions
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insertions (Control)
Study: 9008270
Drug: Didanosine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (200 mg q 12h) for 3 days, followed by didanosine (200 mg q 12h) and ciprofloxacin (750 mg q 12h) for 3 days, and then another course of didanosine (200 mg q 12h for 3 days)
Study: 9008270
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg q 12h) for 3 days, followed by the combination with didanosine, and then ciprofloxacin (750 mg q 12h for 3 days)
Study: 8353827
Drug: Levoprotiline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levoprotiline (150 mg)
Study: 8353827
Drug: Maprotiline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (150 mg)
Study: 3621988
Drug: Diflunisal (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (1000 mg daily)
Study: 27974114
Drug: Porcine pulmonary
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine pulmonary surfactant (PS) + budesonide suspension (0.25 mg/kg)
Study: 24355814
Drug: Spot-on formulation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spot-on formulation containing polyunsaturated fatty acids (PUFAs) and essential oils
Study: 10780315
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg + Bezafibrate 400 mg
Study: 10780315
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg + Bezafibrate 400 mg
Study: 10780315
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Fluvastatin + Bezafibrate)
Study: 26814241
Drug: Local methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local methylcobalamin combined with lidocaine injection for 14 days (IE-Tr)
Study: 26814241
Drug: Local methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local methylcobalamin combined with lidocaine injection for 14 days (ES-Tr)
Study: 26814241
Drug: Local methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local methylcobalamin combined with lidocaine injection (ES-Tr)
Study: 26814241
Drug: Local methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local methylcobalamin combined with lidocaine injection (IE-Tr)
Study: 26814241
Drug: Local methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local methylcobalamin combined with lidocaine injection (IE-Tr and ES-Tr)
Study: 11323542
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment (twice a day ferrous iron, equivalent to 2 x 100 mg elemental iron)
Study: 3285832
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg torasemide
Study: 3285832
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg torasemide
Study: 3285832
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg torasemide (increased to 20 mg)
Study: 29432518
Drug: Biannual structured
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual structured medication reviews by physician, pharmacist, and nurse.
Study: 25130998
Drug: Lapatinib (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1500 mg)
Study: 25130998
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg)
Study: 25130998
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus Trastuzumab (lapatinib 1000 mg, trastuzumab same dose as single agent)
Study: 22720689
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of gentamicin in combination with metronidazole 30 to 60 minutes prior to operation
Study: 22720689
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of gentamicin and metronidazole for 24 hours post-operation
Study: 15951466
Drug: NN414 (0.625-12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN414 (0.625-12.5 mg/kg)
Study: 7562241
Drug: Cyclosporin G
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin G (CsG) at low dose (5 mg/kg/day)
Study: 7562241
Drug: Cyclosporin G
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin G (CsG) at high dose (10 mg/kg/day)
Study: 7562241
Drug: Cyclosporin G
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin G (CsG) during tapering to lower doses
Study: 2109330
Drug: 35% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% CO2 in oxygen inhalation
Study: 6791936
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection of synthetic salmon calcitonin (2-200 i.u.)
Study: 6791936
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of synthetic salmon calcitonin (10-200 i.u. thrice weekly for up to 2 months)
Study: 6791936
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of synthetic salmon calcitonin
Study: 6791936
Drug: Calcium absorption
Normalized name: Evening Primrose Oil Oral Capsule, Liquid Filled [CALCIUM ABSORPTION FOR WOMEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium absorption (six studies) during treatment
Study: 27981804
Drug: SAP therapy
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAP therapy
Study: 26547349
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg/kg loading dose, followed by 0.3 µg·kg(‐1)·h(‐1) continuous infusion)